Radiogenomics: Using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy

Cancer Discovery

Volumn 4, Issue 2, 2014, Pages 155-165

  Kerns, Sarah L ^a,c   Ostrer, Harry ^c   Rosenstein, Barry S ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TESTOSTERONE 17BETA DEHYDROGENASE; TRANSFORMING GROWTH FACTOR BETA;

AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENTAL CARIES; DEPIGMENTATION; DNA REPAIR; EDEMA; EXTERNAL BEAM RADIOTHERAPY; FIBROSIS; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOMICS; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; HYPERSENSITIVITY; META ANALYSIS (TOPIC); MOUTH PAIN; OUTCOME ASSESSMENT; PAIN; QUALITY OF LIFE; RADIATION DERMATITIS; RADIATION PNEUMONIA; RADIATION SICKNESS; RADIOGENOMICS; RADIOSENSITIVITY; REVIEW; SEXUAL DYSFUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TELANGIECTASIA; TOXICITY;

BIOLOGICAL MARKERS; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RADIATION INJURIES; RADIATION TOLERANCE; RADIOTHERAPY;

EID: 84893439855     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0197     Document Type: Review

References (77)

1. Boyle P, Levin B. World cancer report 2008. Lyon, France: International Agency for Research on Cancer (IARC); 2008.
2. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013; 132: 1133-45.
3. Aziz NM. Cancer survivorship research: state of knowledge, challenges and opportunities. Acta Oncol 2007; 46: 417-32.
4. Vale C, Nightingale A, Spera N, Whelan A, Hanley B, Tierney JF. Late complications from chemoradiotherapy for cervical cancer: reflections from cervical cancer survivors 10 years after the national cancer institute alert. Clin Oncol (R Coll Radiol) 2010; 22: 588-9.
5. Miller RC, Schwartz DJ, Sloan JA, Griffin PC, Deming RL, Anders JC, et al. Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4. Int J Radiat Oncol Biol Phys 2011; 79: 1460-6.
6. Syndikus I, Morgan RC, Sydes MR, Graham JD, Dearnaley DP. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). Int J Radiat Oncol Biol Phys 2010; 77: 773-83.
7. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011; 306: 1205-14.
8. Hopwood P, Haviland JS, Sumo G, Mills J, Bliss JM, Yarnold JR. Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials. Lancet Oncol 2010; 11: 231-40.
9. Cancer Research UK. Available from: http://www.cancerresearchuk.org. [Accessed on 7/10/2013.]
10. Stone HB, Coleman CN, Anscher MS, McBride WH. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol 2003; 4: 529-36.
11. Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 2006; 6: 702-13.
12. Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharoah PD, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009; 9: 134-42.
13. Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A, et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999; 85: 2460-8.
14. Talcott JA, Manola J, Clark JA, Kaplan I, Beard CJ, Mitchell SP, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol 2003; 21: 3979-86.
15. Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2013; 85: 444-50.
16. Keller LM, Sopka DM, Li T, Klayton T, Li J, Anderson PR, et al. Fiveyear results of whole breast intensity modulated radiation therapy for the treatment of early stage breast cancer: the Fox Chase Cancer Center experience. Int J Radiat Oncol Biol Phys 2012; 84: 881-7.
17. Barnett GC, Wilkinson JS, Moody AM, Wilson CB, Twyman N, Wishart GC, et al. The Cambridge Breast Intensity-Modulated Radiotherapy Trial: patient-and treatment-related factors that influence late toxicity. Clin Oncol (R Coll Radiol) 2011; 23: 662-73.
18. Barnett GC, De Meerleer G, Gulliford SL, Sydes MR, Elliott RM, Dearnaley DP. The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clin Oncol (R Coll Radiol) 2011; 23: 613-24.
19. Vogelius IR, Bentzen SM. A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol 2012; 51: 975-83.
20. Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys 1989; 16: 1623-30.
21. Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl 1985; 8: S13-9.
22. Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 2010; 76: S3-9.
23. Gatti RA, Berkel I, Boder E, Braedt G, Charmley P, Concannon P, et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature 1988; 336: 577-80.
24. Pollard JM, Gatti RA. Clinical radiation sensitivity with DNA repair disorders: an overview. Int J Radiat Oncol Biol Phys 2009; 74: 1323-31.
25. Gatti RA. The inherited basis of human radiosensitivity. Acta Oncol 2001; 40: 702-11.
26. Safwat A, Bentzen SM, Turesson I, Hendry JH. Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. Int J Radiat Oncol Biol Phys 2002; 52: 198-204.
27. Ozsahin M, Crompton NE, Gourgou S, Kramar A, Li L, Shi Y, et al. CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: a prospective study in 399 patients. Clin Cancer Res 2005; 11: 7426-33.
28. Crompton NE, Miralbell R, Rutz HP, Ersoy F, Sanal O, Wellmann D, et al. Altered apoptotic profiles in irradiated patients with increased toxicity. Int J Radiat Oncol Biol Phys 1999; 45: 707-14.
29. Crompton NE, Shi YQ, Emery GC, Wisser L, Blattmann H, Maier A, et al. Sources of variation in patient response to radiation treatment. Int J Radiat Oncol Biol Phys 2001; 49: 547-54.
30. Rosenstein BS. Identification of SNPs associated with susceptibility for development of adverse reactions to radiotherapy. Pharmacogenomics 2011; 12: 267-75.
31. Andreassen CN, Alsner J. Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. Radiother Oncol 2009; 92: 299-309.
32. Popanda O, Marquardt JU, Chang-Claude J, Schmezer P. Genetic variation in normal tissue toxicity induced by ionizing radiation. Mutat Res 2009; 667: 58-69.
33. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-91.
34. West C, Rosenstein BS. Establishment of a radiogenomics consortium. Radiother Oncol 2010; 94: 117-8.
35. West C, Rosenstein BS, Alsner J, Azria D, Barnett G, Begg A, et al. Establishment of a Radiogenomics Consortium. Int J Radiat Oncol Biol Phys 2010; 76: 1295-6.
36. Palmer LJ, Cardon LR. Shaking the tree: mapping complex disease genes with linkage disequilibrium. Lancet 2005; 366: 1223-34.
37. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006; 38: 652-8.
38. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007; 39: 631-7.
39. Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007; 39: 638-44.
40. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39: 645-9.
41. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40: 310-5.
42. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008; 40: 316-21.
43. Wasserman NF, Aneas I, Nobrega MA. An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer. Genome Res 2010; 20: 1191-7.
44. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-57.
45. Andreassen CN, Barnett GC, Langendijk JA, Alsner J, De Ruysscher D, Krause M, et al. Conducting radiogenomic research-do not forget careful consideration of the clinical data. Radiother Oncol 2012; 105: 337-40.
46. Gogele M, Minelli C, Thakkinstian A, Yurkiewich A, Pattaro C, Pramstaller PP, et al. Methods for meta-analyses of genome-wide association studies: critical assessment of empirical evidence. Am J Epidemiol 2012; 175: 739-49.
47. Menashe I, Rosenberg PS, Chen BE. PGA: power calculator for case-control genetic association analyses. BMC Genet 2008; 9: 36.
48. Epidemiology and Genomics Research. The radiogenomics consortium. [updated 2013 Jun 28]. Available from: http://epi.grants.cancer. gov/radiogenomics/. [Accessed on 7/10/2013.]
49. Kerns SL, Ostrer H, Stock R, Li W, Moore J, Pearlman A, et al. Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010; 78: 1292-300.
50. Kerns SL, Stock R, Stone N, Buckstein M, Shao Y, Campbell C, et al. A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of erectile dysfunction following radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2013; 85: e21-8.
51. Kerns SL, Stone NN, Stock RG, Rath L, Ostrer H, Rosenstein BS. A two-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms following radiotherapy for prostate cancer. J Urol 2013; 190: 102-8.
52. Kerns SL, Stock RG, Stone NN, Blacksburg SR, Rath L, Vega A, et al. Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer. Radiother Oncol 2013; 107: 372-6.
53. Barnett GC, Coles CE, Elliott RM, Baynes C, Luccarini C, Conroy D, et al. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol 2012; 13: 65-77.
54. Barnett GC, Elliott RM, Alsner J, Andreassen CN, Abdelhay O, Burnet NG, et al. Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. Radiother Oncol 2012; 105: 289-95.
55. Barnett GC, Coles CE, Burnet NG, Pharoah PD, Wilkinson J, West CM, et al. No association between SNPs regulating TGF-beta1 secretion and late radiotherapy toxicity to the breast: results from the RAPPER study. Radiother Oncol 2010; 97: 9-14.
56. Talbot CJ, Tanteles GA, Barnett GC, Burnet NG, Chang-Claude J, Coles CE, et al. A replicated association between polymorphisms near TNFalpha and risk for adverse reactions to radiotherapy. Br J Cancer 2012; 107: 748-53.
57. Barnett GC, West CM, Coles CE, Pharoah PD, Talbot CJ, Elliott RM, et al. Standardized Total Average Toxicity score: a scale-and grade-independent measure of late radiotherapy toxicity to facilitate pooling of data from different studies. Int J Radiat Oncol Biol Phys 2012; 82: 1065-74.
58. Burnet NG, Elliott RM, Dunning A, West CM. Radiosensitivity, radiogenomics and RAPPER. Clin Oncol (R Coll Radiol) 2006; 18: 525-8.
59. Barnett GC, Wilkinson J, Moody AM, Wilson CB, Sharma R, Klager S, et al. A randomised controlled trial of forward-planned radiotherapy (IMRT) for early breast cancer: baseline characteristics and dosimetry results. Radiother Oncol 2009; 92: 34-41.
60. Barnett GC, Wilkinson JS, Moody AM, Wilson CB, Twyman N, Wishart GC, et al. Randomized controlled trial of forward-planned intensity modulated radiotherapy for early breast cancer: interim results at 2 years. Int J Radiat Oncol Biol Phys 2012; 82: 715-23.
61. Best T, Li D, Skol AD, Kirchhoff T, Jackson SA, Yasui Y, et al. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med 2011; 17: 941-3.
62. Hosking FJ, Feldman D, Bruchim R, Olver B, Lloyd A, Vijayakrishnan J, et al. Search for inherited susceptibility to radiation-associated meningioma by genomewide SNP linkage disequilibrium mapping. Br J Cancer 2011; 104: 1049-54.
63. Takahashi M, Saenko VA, Rogounovitch TI, Kawaguchi T, Drozd VM, Takigawa-Imamura H, et al. The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl. Hum Mol Genet 2010; 19: 2516-23.
64. Michikawa Y, Suga T, Ishikawa A, Hayashi H, Oka A, Inoko H, et al. Genome wide screen identifies microsatellite markers associated with acute adverse effects following radiotherapy in cancer patients. BMC Med Genet 2010; 11: 123.
65. Niu N, Qin Y, Fridley BL, Hou J, Kalari KR, Zhu M, et al. Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res 2010; 20: 1482-92.
66. Simoni M, Weinbauer GF, Gromoll J, Nieschlag E. Role of FSH in male gonadal function. Ann Endocrinol 1999; 60: 102-6.
67. Themmen APN, Huhtaniemi IT. Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr Rev 2000; 21: 551-83.
68. Ho AY, Atencio DP, Peters S, Stock RG, Formenti SC, Cesaretti JA, et al. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol Biol Phys 2006; 65: 646-55.
69. Wu L, Einstein M, Geissler WM, Chan HK, Elliston KO, Andersson S. Expression cloning and characterization of human 17 betahydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity. J Biol Chem 1993; 268: 12964-9.
70. Sun T, Oh WK, Jacobus S, Regan M, Pomerantz M, Freedman ML, et al. The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness. Cancer Prev Res 2011; 4: 2044-50.
71. Cummings RJ, Mitra S, Foster TH, Lord EM. Migration of skin dendritic cells in response to ionizing radiation exposure. Radiat Res 2009; 171: 687-97.
72. Nardelli B, Zaritskaya L, Semenuk M, Cho YH, LaFleur DW, Shah D, et al. Regulatory effect of IFN-kappa, a novel type I IFN, on cytokine production by cells of the innate immune system. J Immunol 2002; 169: 4822-30.
73. Robbins ME, Zhao W. Chronic oxidative stress and radiation-induced late normal tissue injury: a review. Int J Radiat Biol 2004; 80: 251-9.
74. Pati D, Keller C, Groudine M, Plon SE. Reconstitution of a MEC1-independent checkpoint in yeast by expression of a novel human fork head cDNA. Mol Cell Biol 1997; 17: 3037-46.
75. Ritchie MD. The success of pharmacogenomics in moving genetic association studies from bench to bedside: study design and implementation of precision medicine in the post-GWAS era. Hum Genet 2012; 131: 1615-26.
76. Cesaretti JA, Stock RG, Atencio DP, Peters SA, Peters CA, Burri RJ, et al. A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy. Int J Radiat Oncol Biol Phys 2007; 68: 1410-6.
77. Tucker SL, Li M, Xu T, Gomez D, Yuan X, Yu J, et al. Incorporating single-nucleotide polymorphisms into the Lyman model to improve prediction of radiation pneumonitis. Int J Radiat Oncol Biol Phys 2013; 85: 251-7.